Novel and reported compensatory mutations in rpoABC genes found in drug resistant tuberculosis outbreaks.

ABSTRACT:

Background

Rifampicin (RIF) is a key first-line drug used to treat tuberculosis, a primarily pulmonary disease caused by Mycobacterium tuberculosis. RIF resistance is caused by mutations in rpoB, at the cost of slower growth and reduced transcription efficiency. Antibiotic resistance to RIF is prevalent despite this fitness cost. Compensatory mutations in rpoABC genes have been shown to alleviate the fitness cost of rpoB:S450L, explaining how RIF resistant strains harbor this mutation can spread so rapidly. Unfortunately, the full set of RIF compensatory mutations is still unknown, particularly those compensating for rarer RIF resistance mutations.

Objectives

We performed an association study on a globally representative set of 4,309 whole genome

SUBMITTER: Conkle-Gutierrez D 

PROVIDER: S-EPMC10800992 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature